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Expansion of CD4CD25and FOXP3 Regulatory T Cells
during the Follicular Phase of the Menstrual Cycle:
Implications for Human Reproduction1
Lourdes Arruvito,* Marianela Sanz,* Alison H. Banham,† and Leonardo Fainboim2*‡
Regulatory T cells (Tregs) are thought to affect the severity of various infectious and autoimmune diseases. The incidence of
autoimmune disease is higher in fertile women than in men. Thus, we investigated whether Treg numbers were modulated during
the menstrual cycle by sex hormones. In fertile nonpregnant women, we detected an expansion of CD4CD25FOXP3 Tregs in
the late follicular phase of the menstrual cycle. This increase was tightly correlated with serum levels of estradiol and was followed
by a dramatic decrease in Treg numbers at the luteal phase. Women who have had recurrent spontaneous abortions (RSA) showed
similarly low numbers of Tregs at both the follicular and luteal phases, comparable to numbers we observed in postmenopausal
women. In addition to decreased numbers, Tregs from women with RSA were also functionally deficient, as higher numbers were
required to exert a similar magnitude of suppression to CD4CD25FOXP3 cells from fertile women. Consequently, repro-
ductive failure might result from the inability of Tregs in women with RSA to expand during the preimplantatory phase combined
with their lower functional capacity. Additionally, the modulation of Treg numbers we observed in fertile women suggests that the
stage of the menstrual cycle should be taken into account when Treg numbers are investigated clinically. The Journal of Im-
munology, 2007, 178: 2572–2578.
P henotypically, human CD4
CD25 regulatory T cells
(Tregs)3 are broadly comparable to their murine counter-
parts; they constitutively express CD25, glucocorticoid-
induced TNF receptor family-related gene, intracellular CTLA-4,
and the transcription factor forkhead box P3 (FOXP3), which is the
established marker for Tregs in mice and humans (1).
There is clear evidence that when Tregs are depleted through
mutation of the FOXP3 gene, both mice and humans develop se-
vere autoimmune disease (2, 3). Tregs control the size of the pe-
ripheral T cell pool, modulate immune responses to infection or to
the presence of tumors, and contribute to inducing tolerance after
solid organ transplantation. They also participate in the mainte-
nance of immunological self-tolerance by suppressing immune re-
sponses mediated by autoreactive T cells that lead to autoimmune
disease. In this context, Tregs are implicated in controlling several
autoimmune diseases, such as type I diabetes (4), multiple sclero-
sis (5, 6), and rheumatoid arthritis (7). Additionally, Tregs were
reported to be defective in autoimmune polyglandular syndrome
type II (8), autoimmune hepatitis (9), and in patients with primary
biliary cirrhosis (10). In patients with metastatic melanoma, both
the number and suppressor effects of Tregs were increased (11).
Supporting their role in response to viral infections, Treg numbers
are higher in patients who progressed to the chronic phase of hep-
atitis C virus infection (12). However, apart from situations where
there is almost total absence of these cells, some of the most cru-
cial evidence for their participation in maintaining tolerance is
their role in mediating maternal tolerance of the fetus (13–16).
Pregnancy constitutes a major challenge to the maternal immune
system, because the persistence of paternal alloantigens must be
tolerated while defenses against pathogens are maintained. Al-
though localized mechanisms contribute to fetal protection from
immune attack, maternal alloreactive lymphocytes persist. The hor-
mone estradiol, which increases during pregnancy, might provide one
explanation for enhanced maternal Treg development during gesta-
tion. The influence of estrogens on the incidence and course of
autoimmune diseases has been clearly established in murine models
of systemic lupus erythematosus (17), autoimmune encephalomyelitis
(18–19), and multiple sclerosis (20). Additionally, estrogen is known
to drive expansion of the CD4CD25 regulatory T cell compart-
ment and promote suppressive function by inducing Treg proliferation
(21–23). In the present study, we found that the Treg population
expanded during the follicular phase of the menstrual cycle. Although
the estrogen levels in women with recurrent spontaneous abortions
(RSA) and healthy nonpregnant women were similar, Tregs from
women with RSA were reduced in both number and functionality,
indicating that Treg expansion requires additional stimuli that might
be altered in RSA.
Patients and Methods
Subjects
We evaluated Tregs in samples of peripheral blood obtained from four
different groups: group I included 75 women with a history of three or more
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consecutive RSA that occurred before week 12 of gestation. In these sub-
jects we previously excluded any infectious, endocrine, and anatomic dis-
ease that might have caused the abortion (mean age 30.13 years, range
22–45 years). Group II included 60 fertile women (who had at least one
successful pregnancy and no previous abortions) whose menstrual cycles
were regular (mean age 34.19 years, range 22–42 years). None of the
women from group I or II was taking oral contraceptives.
In group III we included 55 postmenopausal women, who had entered
menopause at least 2 years earlier and were not using hormone replacement
therapies (mean age 57 years, range 46–67 years). Their estrogen levels
were 20 pg/ml, and the progesterone levels were 0.5 ng/ml. Group IV
comprised 52 men (mean age 34.17 years, range 27–44 years). All subjects
were off any therapy at the time of the study. This investigation was ap-
proved by the “Investigation and Ethics Committee at the Hospital de
Clı́nicas José de San Martı́n,” and informed consent was obtained from all
subjects enrolled.
Cell isolation
PBMCs were isolated from 10 ml of heparinized peripheral blood through
a density gradient centrifugation using the Ficoll-Hypaque technique (Am-
ersham Biosciences). Cells were washed twice in PBS (Sigma-
Aldrich) before their use in the following studies.
Flow cytometry
PBMCs were depleted of monocytes by adherence to plastic petri dishes
for 1 h at 37°C and were stained with FITC or PE-labeled mAb specific for
CD4, CD25, CD14, CD45, and CD8 (BD Biosciences). Negative control
samples were incubated with an isotype-matched Ab. Cells were analyzed
in a FACSCalibur cytometer using WinMDI software (BD Biosciences).
Dead cells were excluded by forward and side scatter characteristics. Sta-
tistical analyses are based on at least 30,000 events gated on the population
of interest. As the overall numbers of CD4 cells remained constant, the
frequency of the CD4CD25 population was expressed as a percentage of
all CD4 T lymphocytes.
Intracellular staining for detecting endogenous FOXP3
The flow cytometry analysis was performed according to the method de-
scribed by Roncador et al. (24). In brief, 1  106 cells were fixed in 1 ml
of PBS with 1% paraformaldehyde containing 0.05% Tween 20. After an
overnight incubation at 4°C, cells were treated twice with 0.5 ml of RNase-
free DNase at 100 U/ml (Promega). Staining steps were performed for 1 h
at room temperature. Cells were incubated with a mouse anti-
human-FOXP3 IgG mAb (clone 236A/E7, provided by A.H.B.) and
washed with PBS supplemented with 3% heat-inactivated FCS (Natocor),
0.50% Tween 20, and 0.05% azide. FOXP3 mAb binding was detected
using Alexa Fluor-488 goat anti-mouse-IgG (Molecular Probes) and
washed as described above. Cell surface staining was then performed using
the mAb Cy-Chrome-anti-human-CD4 (BD Pharmingen) and PE-anti-
human-CD25 (BD Biosciences) for 20 min at room temperature followed
by washing in PBS. Cells were analyzed using a FACSCalibur cytometer
(BD Biosciences).
Suppression assay
CD4CD25 Tregs were purified using the Dynal CD4CD25 Treg kit
(Dynal Biotech) according to the manufacturer’s protocols. In brief, in the
first step, PBMCs were incubated with Abs against B cells, NK cells,
monocytes, CD8 T cells, erythrocytes, and CD45RA cells, which were
depleted by mixing with Dynabeads (immunomagnetic negative selection).
In the second step, CD25 Dynabeads were added to purified CD4 cells to
positively isolate the regulatory CD4CD25 T cells. After positive se-
lection, CD4CD25 cells were detached by adding DETACHaBEAD.
Approximately 2  108 PBMCs were isolated from 200 ml of heparinized
peripheral blood through a density gradient centrifugation using the Ficoll-
Hypaque technique (Amersham Biosciences) and were then used to purify
the Treg cells. We conducted seven experiments in which the purity of
isolated Tregs was between 83 and 90%. We obtained similar yields both
in fertile women and in women with RSA. After isolation, 1  106 purified
CD4CD25 cells were stained with anti-FOXP3 mAb 236A/E7. The ex-
pression of FOXP3, determined in three different samples of purified
CD4CD25 cells, was between 65 and 77%. APCs were isolated from
PBMCs depleted of CD3 cells by negative immunomagnetic selection
(Dynabeads M-450 CD3 pan T; Dynal Biotech). A MLR was performed by
mixing 3  104 APCs with 3  104 CD4CD25 cells from the same
female donor and stimulating them with 5  104 mitomycin-treated PB-
MCs from two fully HLA-mismatched allogeneic male donors per well.
Autologous controls were included by mixing 3  104 APCs with 3  104
CD4CD25 cells. The suppressor activity was measured by adding the
following ratios of CD4CD25 cells compared with CD4CD25 cells
to the MLR: 1:1 (e.g., 3  104 CD4CD25 and 3  104 CD4CD25)
or 1:0.5, 1:0.25, and 1:0.125, in 200-l final volumes. Cells were cultured
in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% heat-in-
activated FCS, 200 mM L-glutamine (Sigma-Aldrich), and gentamicin for
5 days. Cell proliferation was measured by adding 1 C of [3H]thymidine
(PerkinElmer Life and Analytical Sciences) for the last 18 h of culture. In
addition, CD4CD25 cells mixed with APC and stimulator cells were
also cultured for the same period of time to assess their state of anergy
(ratio CD25/CD25  0:1), and the response was always lower than that
in the autologous control. CD4CD25 cells cultured without Tregs were
used as a control to measure baseline proliferation before suppression by
Tregs (ratio CD25 /CD25  1:0).
The percentage of suppression was calculated as follows:
[(MLR plus ratio of CD25:CD25)  (autologous control)]
(MLR without CD4CD25)  (autologous control)
 100
The percentage of suppression was plotted against CD4CD25/
CD4CD25 cell ratios, and a regression line was calculated. The I50 was
determined as the ratio that produced 50% suppression [suppressive index
(SI)  100  I50].
Hormone levels
Estradiol (E2) was quantified in the serum of subjects from groups I, II, and
III by radioimmunoassay (Coat-A-Count estradiol-6; Diagnostic Products
Corporation (DPC)). Progesterone was also quantified in the serum of the
same three groups by a chemiluminescent method (Immulite; DPC).
Statistical analysis
We performed statistical analyses using GraphPad Prism version 3.0 for
Windows (GraphPad). Paired t test with equal variance was used to analyze
paired samples. When comparing two groups, significant differences were
determined by two-tailed unpaired t test. Pearson’s correlation was used to
analyze correlations between the levels of estradiol and Tregs during the
menstrual cycle. The Mann-Whitney U test was used to evaluate possible
differences in CD4CD25 function between women with RSA and fertile
women. The p values were considered significant if they were 0.05. The
data had a normal distribution.
Results
Estrogen levels are associated with Treg numbers
Peripheral blood samples from a single fertile donor were collected
at days 3, 9, 12, 19, and 24 in two consecutive menstrual cycles.
At each point we quantified the number of CD4 cells, the pro-
portion of CD4CD25 and CD4CD25high cells within the
CD4 population, the frequency of CD4 cells expressing the
FOXP3 protein, and the serum levels of E2 and progesterone
(Table I). The presence of a biphasic cycle was confirmed when
progesterone level was higher than 8 ng/ml. Fig. 1 depicts a rep-
resentative staining profile of FOXP3 vs CD4 vs CD25 FACS
at days 3, 12, 19, and 24, which corresponds to one menstrual
cycle investigated in a fertile woman. This particular cycle shows
the highest percentage of FOXP3 cells at day 12.
This preliminary observation was confirmed by investigating the
frequency of CD4CD25, CD4CD25high, and FOXP3 cells
during the late follicular phase (days 9–13) or the luteal phase
(days 20–24) in 31 normal healthy fertile women (group II). Dur-
ing the late follicular phase, the frequency of CD4CD25 cells
was 21.76  1.45%, which decreased significantly to 16.43 
0.70% in the luteal phase; p  0.0001. Analysis of the frequency
of the CD4CD25high subset within the CD4 population, which
is known to have suppressive activity and to contain most of the
FOXP3 cells (24) also showed an increase in the late follicular
phase compared with the luteal phase (0.83  0.07% vs 0.61 
0.07%; p  0.01). Similarly, the proportion of FOXP3 cells
within the CD4 population also increased at the late follicular
phase in comparison with the luteal phase (6.14  0.39% vs
3.77  0.42%; p  0.0003). To exclude the possibility that values
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obtained in fertile women were associated with previous pregnan-
cies, we compared our data with those of a panel of 10 healthy
women without prior pregnancies. These data also showed Treg
expansion during the late follicular phase, having values compa-
rable to those of fertile women (CD4CD25: 21.71  2.8% and
FOXP3: 5.4  0.8%). Thus, both female control groups had sim-
ilar frequencies of Tregs during the menstrual cycle.
In this large cohort of healthy women, we also confirmed the
strong positive association between the proportion of
CD4CD25, CD4CD25high, and FOXP3 cells within the
CD4 population and estrogen level (R2  0.76, p  0.0001; R2 
0.60, p  0.0001, and R2  0.78; p  0.0001, respectively). Data
also showed a positive correlation between age and FOXP3 ex-
pression (R2  0.48, p  0.0001) and age and E2 level (R2  0.40,
p  0.0001; Fig. 2). There was no correlation between progester-
one level and the Treg pool (data not shown). Five women with
very low levels of progesterone, indicative of the absence of ovu-
lation, were excluded from this analysis.
Decreased Treg frequencies in women with RSA compared with
fertile women
In both mice and humans it has been reported that an expansion of
Treg cells is necessary to mediate maternal tolerance to the fetus
(13–16). It was thus of interest to investigate the normal behavior
of Tregs during the menstrual cycle of women who had 3 or more
recurrent spontaneous abortions. In particular, we explored
whether the Treg pool expanded during the menstrual cycle of
these women. We analyzed the frequency of Tregs within the
CD4 population during the follicular phase and luteal phase of 36
women with RSA from group I. The frequencies of CD4CD25,
CD4CD25high, and FOXP3 cells at the late follicular phase
were 15.95  1.4%, 0.54  0.06%, and 2.91  0.40%, respec-
tively. During the luteal phase the values observed were 14.45% 
0.46, 0.62%  0.09, and 3.99%  0.32, respectively.
Neither the Treg pool nor age correlated with E2 level (data not
shown). In contrast, similar to results from fertile controls, we
found a positive association between age and FOXP3 expression in
women with RSA (R2  0.6, p  0.0001; Fig. 2, F and G)
In comparison with fertile women, those with RSA showed sig-
nificantly limited expansion of Tregs at the late follicular phase:
15.95  1.44% vs 21.76  1.45%, p  0.0073; 0.54  0.06% vs
0.83  0.07%, p  0.004; 2.91  0.40% vs 6.14  0.39%, p 
0.0001 for CD4CD25, CD4CD25high, and FOXP3, respec-
tively (Fig. 3).
At the beginning of the present study, because we were unaware
that Tregs were modulated during the menstrual cycle, we inves-
tigated the frequency of Tregs in patients and controls only at the
luteal phase (days 20–24). With this approach we recruited a
higher number of controls (n  60) and RSA patients (n  75). In
these samples, the frequencies of CD4CD25, CD4CD25high,
and FOXP3 in RSA patients compared with fertile controls were
15.24  0.36% vs 17.62  0.47%, p  0.0001; 0.77  0.06% vs
0.99  0.05%, p  0.007; 3.16  0.39% vs 4.36  0.42%, p 
0.046, respectively.
Men have comparable frequencies of Tregs to women at the late
follicular phase of their cycle
It was of interest to compare the relative frequency of Tregs in men
with those in fertile and postmenopausal women (Fig. 4). The fre-
quency of CD4CD25, CD4CD25high, and FOXP3 cells
within the CD4 population from men (n  52) was 19.63 
0.68%, 0.69  0.06%, and 7.18  0.77%, respectively. This is not
significantly different from the frequencies in fertile women at the
late follicular phase. In contrast, the frequencies of CD4CD25
and CD4CD25high in postmenopausal women were 15.45% 
0.35 and 0.57%  0.08, which are comparable to those detected in
women with RSA (FOXP3 frequencies were not analyzed in post-
menopausal women).
Differential suppressor capacity of Tregs from fertile women
and those with RSA
In several autoimmune diseases, in addition to their well-known
female prevalence, it was recently demonstrated that Treg popu-
lations in these patients are functionally defective (4–10). The
hallmark of Tregs is their ability to suppress immune responses by
inhibiting the proliferation and cytokine secretion of effector T
cells (1). After we found that Tregs from women with RSA were
numerically deficient, we also explored their functionality in com-
parison with Tregs from fertile women. Thus, we measured their
ability to inhibit proliferation of CD4CD25 effector cells in
response to paternal allostimulation in an MLR. As described in
Patients and Methods, fixed numbers of purified effectors
CD4CD25 (3  104) cocultured with the same number of au-
tologous APCs were stimulated with 5  104 allogeneic cells. To
Table I. Comparative frequencies of CD4CD25, CD4CD25high, and FOXP3 cells and sex hormone levels during the
menstrual cycle
Day 3a Day 9 Day 12a Day 19 Day 24
First menstrual cycle
Absolute number CD4/lb 900.0 974.0 1150.0 1102.0 957.0
CD4CD25 frequency, %c 13.0 22.0 26.0 15.0 11.0
CD4CD25high frequency, %d 0.97 1.3 1.4 1.0 0.89
FOXP3 expression, %e 3.8 8.3 9.6 7.3 4.1
Estradiol level, pg/ml 30.0 146.0 219.0 106.0 31.0
Progesterone level, ng/ml 0.25 0.20 0.89 11.70 0.43
Second menstrual cycle
Absolute number CD4/lb 953.0 870.0 910.0 890.0 960.0
CD4CD25 frequency, %c 9.9 11.0 17.0 10.0 18.0
CD4CD25high frequency, %d 0.78 0.86 1.12 0.95 1.27
FOXP3 expression, %e 2.7 4.3 8.2 4.0 5.0
Estradiol level, pg/ml 31.0 74.0 173.0 82.0 118.0
Progesterone level, ng/ml 0.20 0.20 0.22 12.3 13.90
a Days of the menstrual cycle.
b Absolute count of CD4 cells acquired from complete blood.
c Frequency of peripheral blood CD4CD25 T lymphocytes expressed as percentage of CD4 T lymphocytes.
d Frequency of peripheral blood CD4CD25high T cell subset expressed as percentage of CD4 T lymphocytes.
e Frequency of FOXP3 expression in peripheral blood CD4 T lymphocytes.
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establish their suppressor activity, different ratios of CD4CD25
cells were added to a fixed number of CD4CD25 target cells:
ratio 1:1 (3  104), ratio 1:0.5 (1.5  104 Tregs), ratio 1:0.25
(0.75  104 Tregs), and ratio 1:0.12 (0.325  104 Tregs). In seven
independent experiments, we compared the suppressor activity of
Tregs from fertile women or those with RSA, on the proliferation
of the CD4CD25 cells stimulated by paternal allogeneic cells.
In each experiment, we compared the suppressive effect of purified
CD4CD25 obtained from a fertile woman vs purified
CD4CD25 from a woman with RSA. In all experiments, addi-
tion of 15,000 Treg cells obtained from fertile women reached the
maximum level of inhibition with an I50 between 15 and 23% and
an SI that ranged between 85 and 77%. In contrast, RSA patients
had an I50 between 43 and 54% and an SI that ranged between 46
and 57% (median  SEM 79.5  1.06 vs 53  1.5; p  0.0006;
Fig. 5A). Results from one representative experiment, depicted in
Fig. 5B, show that higher numbers of Tregs were required from
women with RSA to reach similar levels of MLR inhibition.
We next explored whether the functional deficit is specific to
Tregs or T effectors. We performed three criss-cross experiments
in which patient and control Treg cells were cocultured with the
autologous CD4CD25 effector T cells from either fertile
women or those with RSA. Regulatory T cells from fertile women
similarly suppressed the proliferative response of target
CD4CD25 T cells derived from both controls and RSA patients
(suppression 75%). However, Tregs from women with RSA
showed significantly lower suppression of the proliferative re-
sponse of target cells from either fertile women or women with
RSA (suppression 43%; p  0.02). Hence, Tregs from women
with RSA are both numerically and functionally deficient and
might contribute to reduced immunosuppression during the course
of an alloimmune response (Fig. 6).
Discussion
We demonstrated that Treg frequencies within the CD4 popula-
tion undergo profound changes during the menstrual cycle that
could affect female immunoregulation. We demonstrated that Treg
numbers increased during the follicular phase of the menstrual
cycle. Although our results contrast with a recent study that failed
to detect changes in numbers of Tregs during the menstrual cycle
(22) that study not only did not measure the presence of FOXP3
but also looked at the presence of Tregs at days 6–9 vs 20–24 of
the menstrual cycle. The present study clearly demonstrates that
Tregs reach their maximum numbers during the late follicular
phase (days 9–13). The expansion we detected in the late follicular
phase was tightly correlated with an increase in the serum level of
estrogen. Also observed in fertile women was a dramatic reduction
in the Treg frequency during the luteal phase. The preovulatory
FIGURE 1. Representative FACS profiles comparing CD4CD25FOXP3 populations during the menstrual cycle. A, Intracellular FOXP3 and
CD4CD25 surface staining expression observed at days 3, 12, 19, and 24 during the menstrual cycle of a fertile woman. Data show the frequency of
the CD4CD25FOXP3 population expressed as a percentage of all CD4 T lymphocytes. B, Representative FACS dot plots showing the expansion of
FOXP3 Tregs during the menstrual cycle.
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increase in Tregs might reflect a requirement for induction of im-
mune tolerance to facilitate a successful implantation.
When we investigated the frequency of Tregs in patients and
controls with samples obtained only at the luteal phase, Treg fre-
quencies differed from the ones observed in the smaller group. We
should stress that data from the smaller group were obtained from
the same donor at the follicular phase and luteal phase. Addition-
ally, in the smaller group we excluded individuals without a clear
biphasic cycle, thus, we considered these data more accurate.
In mice, an expansion of regulatory T cells, which also seems to
begin before implantation, mediates maternal tolerance to the fetus
(25) and estrogen has been implicated as the driving force for this
expansion (21, 23). Conversely, the depletion of CD4CD25 T
cells after implantation leads to an early failure of gestation (26).
Interestingly in a murine model of spontaneous abortion, the abor-
tion-prone mice showed deficient Treg activity that could be
treated by adoptive transfer of Tregs from normal pregnant but not
nonpregnant female mice, to prevent abortion (26). In humans,
three independent studies have described both the systemic and
decidual expansion of CD4CD25FOXP3 Treg populations in
the first two trimesters of pregnancy (14–16). Also, the proportion
of Tregs is reported to be much lower in deciduas of women with
RSA (15). In the present study we demonstrate that women with
RSA had similar Treg frequencies in the CD4 population at both
the late follicular and luteal phases of the menstrual cycle. These
findings indicate that women with RSA did not show the Treg
expansion during the follicular phase that we observed in fertile
women. In addition to a decreased Treg frequency, our results also
suggest that Tregs from women with RSA are functionally defi-
cient, because higher numbers are required to exert a suppressive
effect comparable to that of CD4CD25 cells from fertile
women. Anergy, a hallmark of CD4CD25 Tregs was clearly
demonstrated both in women with RSA and in fertile women stim-
ulated by allogeneic cells in an MLR. We also demonstrated that
the decrease in Treg function observed in women with RSA was an
intrinsic functional defect in the CD4CD25 Treg subset rather
than reduced susceptibility of their T-effector cells to Treg-medi-
ated suppression. A previous study suggested that CD4CD25
Tregs completely suppressed the proliferation of Th1 clones with
only a partial inhibition of the proliferation of Th2 clones (27).
This inhibition of the suppressor effect on Th2 cells seems to be
mediated by IL-4 and IL-9. The receptors for these cytokines share
a -chain with IL-2R but possess a distinct -chain (28). During a
normal pregnancy, a Th2 response acting through its anti-
inflammatory capacity might contribute to the embryo’s survival,
which could be enhanced by the differential effects of
CD4CD25 on Th1 and Th2 cells. However, studies from IL-4-
and IL-10-deficient mice do not show disturbed pregnancy, sug-
gesting that, in mice, Th2 cells are not essential for normal preg-
nancy (29).
FIGURE 3. Lower level of Tregs in RSA patients compared with con-
trol women at the late follicular phase. The frequency of CD4CD25,
CD4CD25high, and FOXP3 cells within the CD4 population from con-
trols (n  31) and women with RSA (n  36) was determined by flow
cytometry between days 9 and 12 and days 20 and 24 of the menstrual
cycle. A, Fertile women showed an expansion of Tregs in the late follicular
phase followed by a dramatic decrease in Treg numbers in the luteal phase
of the menstrual cycle. B, Women with RSA had similar numbers of Tregs
at both phases. Data are presented as mean  SEM and p value as analyzed
by unpaired t test.
FIGURE 2. Correlation between the
frequencies of Tregs with estrogen level
at the late follicular phase. The frequency
of CD4CD25 (A), CD4CD25high
(B), and FOXP3 (C) cells within the
CD4 population obtained from each fe-
male donor was determined by flow cy-
tometry between days 9 and 12 of the
menstrual cycle. These frequencies were
compared with the level of estradiol
present on the same day. Data indicate a
strong positive association between the
frequency of all three markers of Tregs
and estrogen level as analyzed by Pear-
son correlation coefficient and coefficient
of determination. D, Positive association
between age and FOXP3 expression in
healthy fertile women. E, Positive asso-
ciation between age and estradiol level in
healthy fertile women. F, Positive asso-
ciation between age and FOXP3 expres-
sion in women with RSA. G, Absence of
correlation between age and estradiol
level in women with RSA.
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In the current study we observed that postmenopausal women,
who would not require expansion of Treg to sustain a successful
pregnancy, showed Treg frequencies that were similar to those
detected in women with RSA. In men, testosterone was shown to
play a critical role in maintaining the level of Tregs, without the
profound changes in Treg frequencies we describe here in women
under the cyclic influence of female sex hormones (30). As dis-
cussed above, the expansion of Tregs during the follicular phase
that was observed in control women was highly correlated with the
levels of serum E2. Treg expansion was not present in women with
RSA, even though they had similar or even higher levels of E2.
Although fertile women showed a positive correlation between age
and E2 level, the same correlation was not observed in women
with RSA. These data suggest that E2 could play a role in the
function of Treg in women with RSA. This effect seems not to be
related to age, because controls and women with RSA showed a
similar correlation between age and FOXP3 expression. Signaling
through IL-2 is known to be required for peripheral expansion and
FIGURE 5. Differential suppressor capacity of CD4CD25 cells from fertile women and those with RSA. CD4CD25 and CD4CD25 cells were
purified by using the Dynal CD4CD25 Treg kit, as described in Patients and Methods. APCs were isolated from PBMCs depleted of CD3 cells by
negative immunomagnetic selection. MLR was performed as described. A, Seven independent experiments examined the number of CD4CD25 Treg
cells from fertile women or women with RSA required to obtain maximum inhibition of the proliferation of CD4CD25 cells. The addition of 15,000
Tregs obtained from a fertile woman reached the maximum level of inhibition. Tregs from women with RSA required almost twice as many cells to reach
similar levels of MLR inhibition. Data were analyzed by the Mann-Whitney U test, p  0.0006. B, One representative experiment. I50 was determined as
the ratio that produced 50% suppression. Suppressive index (SI)  100  I50. Allogeneic response was determined as the ratio CD4
CD25/
CD4CD25  1:0. Anergy was determined as the ratio CD4CD25/CD4CD25  0:1.
FIGURE 4. The frequencies of Treg in men are comparable to the fre-
quencies of Treg in fertile women at the late follicular phase of their cycle.
The frequency of CD4CD25, CD4CD25high, and FOXP3 cells within
the CD4 population from men, fertile women, or women with RSA was
determined by flow cytometry. Values in both subsets of women represent
data obtained between days 9 and 12 of the menstrual cycle. There were no
significant differences in the percentage of CD4CD25, CD4CD25high,
cells and FOXP3 expression between men and fertile women. Data are
presented as mean  SEM and p value as analyzed by unpaired t test.
FIGURE 6. CD4CD25 T cells from RSA patients show low suppres-
sion of effector CD4CD25 T cells isolated from either women with RSA
or fertile controls. In contrast, higher suppressor activity of Tregs from
fertile women is observed both on CD4CD25 effector T cells from fer-
tile controls and individuals with RSA. CD4CD25 cells from RSA pa-
tients and fertile women were purified, and MLR was performed as de-
scribed in Patients and Methods. A total of 3  104 CD4CD25 effector
cells/well from fertile women were cocultured with 1.5  104 autologous
CD4CD25 cells (1st bar) or with the same number of Tregs from RSA
patients (2nd bar). Conversely, 3  104 CD4CD25 effector cells from
RSA patients were cocultured with 1.5  104 autologous CD4CD25
cells (3rd bar) or with CD4CD25 cells from fertile women (4th bar).
One representative result of three independent experiments performed with
different individuals is shown. Data were analyzed using the Mann-Whit-
ney U test, p  0.002.
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suppressive activity of Tregs (31, 32). There is also a distinct IL-2
receptor signaling pattern in CD4CD25 Tregs compared with
activated T lymphocytes in which the Janus/kinase/STAT pathway
remains intact while downstream targets of the PI3K are not acti-
vated (33). In vitro studies suggested that the tumor suppressor
PTEN (phosphatase and tensin homolog deleted on chromosome
10) acts as a negative regulator of IL-2-mediated expansion of
Tregs. Of potential relevance are findings that human PTEN ex-
pression is regulated by ovarian steroids, including estrogen, and
that PTEN expression shows temporal and spatial changes during
the menstrual cycle and during early pregnancy (34). According to
our results, it remains to be elucidated whether Tregs from RSA
patients are capable of a normal response to E2, and an impaired
regulatory function of E2 in RSA patients might be further inves-
tigated. Similarly, additional studies should investigate the role of
PTEN, IL-2, and related cytokines that are known to play a central
role in the expansion and function of Tregs.
In summary, we conclude that a dysregulation in Treg frequency
and functionality in women with RSA might contribute to their
reproductive failure. Additionally, it is strongly recommended that
the profound changes that occur in Treg frequencies during the
normal menstrual cycle should be considered when number of
Tregs is investigated in premenopausal women in a clinical setting.
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